(Reuters) – Novavax Inc. presented its candidate vaccine COVID-19 to the Canadian health regulator for emergency use authorization after the pharmaceutical company said last week that its vaccine was 89% effective in a UK trial.
The candidate vaccine will be analyzed in real time as soon as the Canadian government accepts the application, which was submitted by the company on Friday, according to a notice on the Health Canada website. https://bit.ly/3oCuFTr
Real-time analysis can accelerate the successful vaccine approval process, allowing researchers to send results in real time, even before the final trial data is ready.
Novavax has an agreement with the Government of Canada to provide up to 76 million doses of its vaccine.
A large final-stage trial in the United States and Mexico, which began in December, is also underway.
The vaccines of Moderna Inc and Pfizer Inc have already been authorized for emergency use in Canada.
Last week, Novavax said its vaccine was 89.3% effective in preventing COVID-19 in a UK study, and was almost as effective in protecting against the most highly contagious variant first discovered in the island nation. .
(Reporting by Dania Nadeem in Bengaluru, edited by Sherry Jacob-Phillips)
Originally published